Wet Age-Related Macular Degeneration (AMD) Emerging Therapy and TPP Insights

Thelansis’s “Wet Age-Related Macular Degeneration (AMD) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Wet Age-Related Macular Degeneration (AMD) Overview

Wet Age-Related Macular Degeneration (AMD), also known as neovascular or exudative AMD, is a progressive retinal disorder characterized by the abnormal growth of blood vessels beneath the macula, the central portion of the retina responsible for sharp, detailed vision. These fragile vessels tend to leak blood and fluid, leading to macular scarring and rapid deterioration of central vision, often manifesting as visual distortions, blind spots, or difficulty recognizing faces and reading. Although it accounts for only 10–15% of AMD cases, wet AMD is responsible for the majority of severe vision loss associated with the disease. It typically evolves from the dry form of AMD and can progress swiftly if untreated. Diagnosis relies on imaging modalities such as optical coherence tomography (OCT) and fluorescein angiography, which help visualize fluid accumulation and vascular changes. Treatment has advanced significantly with intravitreal anti-VEGF therapies that inhibit vessel growth and leakage, offering the potential to stabilize or even improve vision if initiated promptly.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk,etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)